Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

Frontline approaches in FLT3-mutated AML

Naval Daver, MD, The University of Texas MD Anderson Cancer Center, Houston, TX, discusses frontline approaches for patients with FLT3-mutated acute myeloid leukemia (AML), including quizartinib with intensive chemotherapy, based on data from the Phase III QuANTUM-First trial (NCT02668653). Dr Daver also highlights high remission rates and improved survival in trials of lower-intensity triplet combination regimens consisting of a hypomethylating agent, venetoclax, and gilteritinib (NCT04140487) or quizartinib (NCT03661307), and notes RAS mutations as a key resistance mechanism. This presentation took place at the 8th International Workshop on Acute Leukemias (iwAL) 2026, held in Cambridge, MA.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

Choose your cookie settings

VJHemOnc uses necessary cookies to make the site work. With your permission we'd also like to use analytics, preference and marketing cookies to understand how the site is used and improve it.

Choose an option to continue. You can change it at any time on our Cookie Policy page, linked at the bottom of every page.